Full Press Release Details
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) --Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Wednesday, May 20, 2026, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2026.
Webcast InformationDate:Wednesday, May 20, 2026Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Webcast Link:https://events.q4inc.com/attendee/135456520
Webcast Link InstructionsYou can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website athttps://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.
About Belite BioBelite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us onX,Instagram,LinkedIn, and Facebook, or visit us atwww.belitebio.com.